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Immune Checkpoint Blockade has revolutionized treatment landscape of many cancers
Hellmann et al NEJM 2018 
Non-small cell lung cancer 
Ledford et al Nature 2018 
Only subset of immunologically “Hot” tumor types responsive to immunotherapy
Hedge et al. Immunity 2019 Responsive Unresponsive
“Hot” “Cold”
PD-1/PD-L1 and CTLA-4 blockade
Targeting tumor intrinsic mechanisms of immune evasion to potentiate immunotherapy
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Cellular Senescence: a two-component damage response connecting 




¤ Modulation of the microenvironment
Potent activation of secreted factors:
• Pro-inflammatory cytokines/chemokines
• Growth and stemness factors
• Matrix metalloproteinases
• Angiogenic factors
¤ Stable cell cycle arrest
Physiological stress response to damage
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Ruscetti et al. Science 2018; Ruscetti et al. Cell 2020 
Therapy-induced senescence mediates divergent 
immune responses in different tissues
KRAS-driven pancreas cancer







































































Tumor volume (T14 vs. T0)
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• Which SASP factors are important for anti-tumor immune responses?
• How is the SASP transcriptionally regulated in different contexts? 






































































Pancreas tumor cells in lung environment
C57BL/6 micePancreas KPC cells
(KrasG12D;Trp53-/-)
Lung tumor cells in pancreas environment



























































EZH2 and SUZ12 are chromatin regulators that suppress SASP
































































































































































































































































































































Studying senescence and immune surveillance bypass 








Prostate cancer Modeling prostate cancer in mice




WT C57BL/6 EPO-GEMMs  
Leibold*, Ruscetti* et al Cancer Discovery 2020Robinson et al Cell 2015
Pipeline to identify and validate senescence-inducing 
compounds in tumor and genotype-specific manner
Chemical Library Screens
In vitro
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